Type I insulin-like growth factor receptor signaling in hematological malignancies

Deeksha Vishwamitra; Suraj Konnath George; Ping Shi; Ahmed O. Kaseb; Hesham M. Amin

doi:10.18632/oncotarget.12123

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Type I insulin-like growth factor receptor signaling in hematological malignancies

Deeksha Vishwamitra, Suraj Konnath George, Ping Shi, Ahmed O. Kaseb and Hesham M. Amin _

PDF | HTML | How to cite

Oncotarget. 2017; 8:1814-1844. https://doi.org/10.18632/oncotarget.12123

Metrics: PDF 2606 views | HTML 5220 views | ?

Abstract

Deeksha Vishwamitra1, Suraj Konnath George1, Ping Shi2, Ahmed O. Kaseb3 and Hesham M. Amin1,4

1 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2 State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China

3 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4 The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA

Correspondence to:

Hesham M. Amin, email:

Keywords: IGF-IR; plasma cell myeloma; leukemia; lymphoma

Received: January 21, 2016 Accepted: September 12, 2016 Published: September 19, 2016

Abstract

The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that the type I IGF receptor (IGF-IR) and its primary ligand IGF-I are important for maintaining the survival of malignant cells of hematopoietic origin. In this review, we discuss current understanding of the role of IGF-IR signaling in cancer with a focus on the hematological neoplasms. We also address the emergence of IGF-IR as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12123

Publication Alerts

Reviews:

Type I insulin-like growth factor receptor signaling in hematological malignancies

Abstract